FUJIFILM Pharmaceuticals U.S.A., Inc.
Clinical trials sponsored by FUJIFILM Pharmaceuticals U.S.A., Inc., explained in plain language.
A subsidiary of FUJIFILM, developing and marketing pharmaceuticals.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a new gemcitabine formulation outsmart advanced solid tumors? Results expected Oct 2026 (estimated)
- New liposome chemo shows promise in early cancer trial Results expected Dec 2026 (estimated)
-
New liposome chemo shows promise in early cancer trial
Disease control OngoingThis early-stage trial tests FF-10850, a liposome-wrapped version of the chemotherapy drug topotecan, in 96 adults with advanced solid tumors like ovarian, cervical, and Merkel cell carcinoma. The main goals are to find the safest dose and understand side effects. Researchers hop…
Phase 1 • Sponsor: Fujifilm Pharmaceuticals U.S.A., Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a new gemcitabine formulation outsmart advanced solid tumors?
Disease control OngoingThis phase 1 trial tests FF-10832, a liposomal version of the chemotherapy drug gemcitabine, in adults with advanced solid tumors, including biliary tract cancer, that have not responded to standard treatment or have no standard options. Researchers give the drug as an intravenou…
Phase 1 • Sponsor: Fujifilm Pharmaceuticals U.S.A., Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug combo aims to shrink Hard-to-Treat cancers
Disease control OngoingThis phase 2a trial tests a new form of the chemotherapy drug gemcitabine (FF-10832) given alone or with the immunotherapy pembrolizumab (Keytruda) in 120 adults with advanced bladder or non-small cell lung cancer. The study first checks safety and finds the best dose, then looks…
Phase 2 • Sponsor: Fujifilm Pharmaceuticals U.S.A., Inc. • Aim: Disease control
Last updated Jun 26, 2026 14:20 UTC